Moonlake Immunotherapeutics pricing of upsized $200M offering

MoonLake Immunotherapeutics (NASDAQ: MLTX) has priced an upsized public offering of Class A Ordinary Shares, raising gross proceeds of approximately $460 million in June 2023. This financing marked a significant milestone for the company, providing substantial capital to advance the development of its lead asset, sonelokimab, and supporting broader corporate initiatives. The offering included 8,000,000 shares at a public offering price of $50.00 per share, with an additional 1,200,000 shares purchased under the underwriters' option, which was exercised in full.

The capital raised through this offering was instrumental in strengthening MoonLake’s financial position, with cash and cash equivalents increasing from $63.1 million as of March 31, 2023, to $501.8 million by June 30, 2023. This influx of capital allowed the company to accelerate its clinical development programs, including Phase 2 MIRA and ARGO trials for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), respectively.

In April 2025, MoonLake further bolstered its financial flexibility by securing a $500 million non-dilutive financing agreement with Hercules Capital. This agreement, which included $75 million drawn at close and additional tranches tied to pre-specified milestones, provided the company with a robust capital base without diluting existing shareholders. The non-dilutive nature of the financing is notable, as it aligns with a growing trend in the biotech sector to preserve equity while securing necessary funding for late-stage development and commercialization.

MoonLake’s strategic approach to financing has enabled the company to maintain a lean cost structure while advancing multiple clinical trials across its pipeline. The company’s focus on a single, high-potential asset—sonelokimab—has allowed it to allocate resources efficiently and maintain a clear path toward regulatory milestones and market entry. As of April 2025, MoonLake was preparing for pivotal data readouts in its Phase 3 VELA program for HS and anticipated interim results from its Phase 2 LEDA trial in palmoplantar pustulosis (PPP).

The company’s financial strategy, supported by both equity and non-dilutive financing, reflects a disciplined approach to capital management and risk mitigation. With a strong balance sheet and a well-defined clinical development plan, MoonLake is positioned to advance its therapeutic candidates through key regulatory and commercialization phases.